Press Room

Press Clipping / Nov 16, 2018

Employee focus on ethical issues keeps firms on a righteous path

Irish Examiner, November 16, 2018

This year, a further seven companies were recertified to the standard: Boots Retail, CRH, Deloitte, ESB, Gas Networks Ireland, Intel and KBC Bank Ireland.

In all, 33 companies have now achieved the BWR mark, which is hosted by Business in the Community Ireland (BITCI), which assesses applicant companies’ sustainability and corporate social responsibility commitments.

Significantly, this year’s event also saw 43 companies pledge to cut their carbon emissions between now and 2030. The signatories are in retail, manufacturing, agri-food, professional services, banks, transport and ICT.

It is becoming increasingly important for Irish companies to measure and prove their commitments to sustainability, the environment and engagement with employees and local communities. And nudging those commitments on are their existing and prospective new employees, who are becoming increasingly insistent on working in a caring workplace.

“We look at companies’ activities across the board, across their various management practices,” said BITCI’s CEO, Tomás Sercovich.

The companies speak very highly of the mark, and that is because we are very thorough about the audit process. We have 22 auditors who conduct best-in-class audits. Companies find it useful to have a third party come in to observe their policies in practice

“The truth is that companies are also very good at using this mark as a way of differentiating themselves in an increasingly complicated employment market. I know there are people working in life sciences who changing jobs, some just crossing the road to take work with a competitor.” In many cases, the employees are citing ethical grounds when changing jobs. Mr Sercovich said many new graduates are now asking companies policy questions about plastic, recycling and carbon footprint at interviews.

In the case of Cork Harbour industries, would-be employees are asking about any impacts on the harbour. In retail, companies are also becoming more attuned to the ethical antennae of their employees. One Dutch supermarket recently introduced a plastic-free aisle.

“Millennials in particular are looking to work with companies who have deep commitments across a range of issues,” Mr Sercovich said. “They’re digging deep with their questions. They won’t accept a box-ticking exercise, they want companies with real values integrated into their business models and their everyday activities.” This is where BITCI’s support is so important to companies. Going for the BWR mark is not without its risks. Attaining the mark is really demanding, so there is a very real risk of being embarrassed by falling short. Several recipients said they were relieved as well as delighted.

“We’re extremely proud to have achieved the Business Working Responsibly mark,” said Maarten Schuurman, managing director, Heineken Ireland. “It’s wonderful to see the emphasis we place on sustainability and responsibility across all aspects of our business recognised and benchmarked independently.

“The mark serves as a clear signal to our stakeholders and our customers and consumers that we are listening; that we know sustainability matters to them as much as it does to us; and that we are working every day to make Heineken Ireland a truly green brewer.” Kathryn D’Arcy, Heineken’s director of corporate affairs, added: “Our commitment to sustainability and the environment is a long journey. We need to make decisions today that will have a positive impact on the world for the people who are coming behind us.

“Heineken has built up a proud heritage over 160 years. We’re producers of premium beers and ciders. Using only quality sustainable ingredients is at the heart of what we do. The Business Working Responsibly mark is a useful part of our journey. We want our heritage and commitments to be around for another 160 years.”

Meanwhile, Hovione in Ringaskiddy is another of this year’s four new companies to achieve the Business Working Responsibly mark. It is also one of those to have signed up to BITCI’s dedicated pledge to significantly reduce their carbon emissions.

“The award fits in well with our commitment to operating sustainably,” said Paul Downing, general manager of Hovione. “We have done a lot of work in managing our carbon footprint.

Achieving the Business Working Responsibly mark is important to us, and we will be celebrating the award with our staff and the on-site team dedicated to managing this for us. The mark is also important in terms of attracting and retaining talented employees

Dr. Downing said it is increasingly a feature for job candidates to ask about companies’ commitments to the environment, their employees and their local community. Membership of BITCI is one useful measure for demonstrating Hovione’s commitments.

“People joining the company frequently ask questions about our corporate social responsibility programme,” said Mr Downing. “The Business Working Responsibly mark is a very useful measure of our environmental and community commitments.”

Hovione is also the first chemical or pharmaceutical company to become B Corp certified. B Corp is a global community of companies committed to collectively solving social and environmental problems.

 

Read the entire article

 

 

Also in the Press Room

See All

The CDMO is preparing for its New Jersey facility to become fully operational this year. Hovione’s multimillion-dollar investment in expanding its East Windsor, NJ manufacturing site is quickly coming to fruition. Contract Pharma will be visiting the site later in April 2026 to provide a unique overview of what’s new. As a preview, the Contract Pharma team met with Hovione at the Drug, Chemical & Associated Technologies Association (DCAT) Week. David Basile, Vice President of Technical Operations—Americas, spoke at the opening Member Company Announcement Forum on March 23, 2026. In this interview, Basile expands on his remarks at the Announcement Forum. As he explains, Hovione is concentrating not only on New Jersey, but also on facilities in Ireland and Portugal. Contract Pharma: Good manufacturing practice (GMP) operations will soon be fully operational at the New Jersey facility. How has Hovione progressed through this process since the initial investment cycle was announced last fall—or even prior? David Basile: It’s been a really great journey and evolution over the last two to three years, conceiving the plan to grow our U.S. footprint. It was one of the reasons I came aboard with Hovione, to grow that footprint and build our commercial manufacturing prowess in the States. In New Jersey, we had originated [the site] as a tech transfer center. [But] we wanted to grow the organization to be more equivalent with our Portugal and Ireland sites, to do more large-scale manufacturing. So, this is part of that journey. And that’s not just bricks-and-mortar and machinery. It’s been people, talent, partnerships with clients, supporting functions such as QC [quality control] and analytical development. We’re growing our R&D teams as well. It’s a comprehensive approach to systems, people, and processes. CP: At the Member Company Announcement Forum, you ran through some of the major technical specifications of the NJ expansion. Can you talk about a few of the highlights and their capabilities? Basile: This year we’ll be starting up two PSD-3 scale spray dryers. This is a useful scale of machinery for our clients. It plays nicely between the PSD-2 and PSD-4 scales that we have elsewhere in the network. I’d say it’s medium-to-large scale capacity; we could do 30 metric tons annually out of this type of a unit. Product to product, that differs, but we do have products that put that kind of volume out in a PSD-3, so it’s not small-scale. Customers want to hear this because [they want to gain] efficiency with their batch size, and turnaround time. And when we campaign, we can really see significant throughput with this line up of new machinery and assets. The first machine that we will start up is a Hastelloy unit, which is unique. We took a pause [in the construction timeline] to make that upgrade, as we had a client that needed this configuration. There are additional clients that are interested in it too, because you can do acidic solutions and more aggressive kinds of formulations as well as solvent-based formulations. So that’s a unique element of that first machine. The second machine is being qualified later this year. Kind of a twin, but this one is standard 316 stainless steel.  CP: When a company brings a new or expanded facility online, new personnel often accompanies the new tech. What is the workforce addition that you expect, and what are the challenges of retaining top talent? Basile: In preparation for commissioning and startup of this new equipment, we’ve already ramped our headcount up, to be ready for GMP launch. We’ve added roughly 20 employees in preparation for this first machine to go [live]. Over the next 18-plus months, we could see something on a similar scale, getting us up to that 40–50 headcount range for that facility once it’s fully operational—and more later on in 2028, when we bring in the CDC [continuous direct compression] Flex unit. That’s what’s really going to be transformative about this new facility: that integrated offering coming to life. CP: Even if the NJ facility is top of mind right now, let’s also touch on some of your plans in Europe. What is your vision for expanding in Europe in the next two to three years? Basile: Ideally, Hovione’s aim is to build an equivalent manufacturing network, where clients can go to any site across the globe and get a similar breadth and scale of offering. We’re doing that now in Ireland, expanding our PSD-4 scale spray drying. One unit was recently installed. Late last year, it went live. Then there’s at least one other new PSD-4 in motion, which is really exciting, because [spray dryers] at this site were historically [exclusive to] larger chemistry manufacturing for API [active pharmaceutical ingredient] synthesis. So now, they’re further building their muscle with additional large scale spray drying capacity. On the Portugal side, there’s a lot of great things going on. Our Tejo campus, in Seixal, Portugal, is a massive, 4.5-million-square-foot plot of land, and there’s a new, modular facility going up there. It’s incredibly exciting. The design of the facility has been well-thought through with material flows [and] gravity-fed processes. Here, we minimize handling and [maximize] speed of processing. It’s scalable. We call each one of these building segments a finger. You can copy and paste these fingers, and they are built to house both spray drying and drug product assets within each unit. So, why is that relevant? Because we can easily scale the number of fingers. When customers say, “we need more capacity,” we have the design on the table ready to go. We know how to execute, we know how to build and implement our technology platforms in a short timeframe. Deployment timeframes are truly becoming more and more relevant to our clients. CP: From last year’s DCAT Week to this year’s, what conversations are you having with industry colleagues about ever-changing geopolitics? Basile: We’re seeing that local, regional manufacturing capacity is vital. The concept of U.S. for U.S. and China for China seems to be a common theme that our clients are talking about. We happen to have an edge, as we [have already] started our journey of expanding our domestic U.S. capacity. So I think that’s a crucial piece to the puzzle, having dual-sided Atlantic manufacturing operations. The traditional global supply chain model is being challenged. Having soup-to-nuts sites that are fully autonomous in development, scale-up, tech transfer, all the way to commercial scale operation, is vital to Hovione, and how we’re protecting our supply chain. [Concerning] starting raw materials and Tier 2 suppliers, our procurement teams are out in the market making sure that there’s no single point of failure for critical materials [like] polymers and solvents that we utilize. We’re managing and mitigating risk by looking at those secondary suppliers across different geographies. CP: Encapsulating your planned expansions on both sides of the Atlantic, how would you sum up the value to the customer? Basile: It’s about speed-to-market. It’s one partner from early-phase development, clinical scale, all the way through commercial. They gain comfort, trust, and not just capacity and equipment time; it’s also about competency and depth of scientific expertise. We’re not just a traditional CDMO. There’s unique expertise in particle science and spray dried dispersions that we offer our clients that they don’t have. [With] traditional CDMOs, customers typically pay for time in [a particular] unit, for example, they’d say: “I need a machine, and I need [it for] three weeks.” Hovione is truly a partner to our clients. They’re leveraging our platforms, our know-how in spray drying, and our know-how in equipment design. Read the article at ContractPharma.com  

Article

Hovione Eyeing Manufacturing Expansion on Both Sides of Atlantic

Apr 06, 2026

With key expansions coming to fruition on either side of the pond, specialist CDMO Hovione is making sure that drugmakers can access its particle engineering expertise across multiple geographies.  That flexibility will be key for the Portugal-based company in the coming years as the pharmaceutical industry continues to embrace more regional supply chains. In a recent interview, Hovione's David Basile, VP of technical operations for the Americas, discussed this trend and the manufacturer's expansion project, which is set to come online in New Jersey next month.  In the coming weeks, Hovione plans to debut a new spray drying expansion at its campus in East Windsor, New Jersey. The company has invested $100 million to expand its campus, including new construction and the acquisition of an additional facility and greenfield land.  Specifically, one of two pharmaceutical spray drying-3 units, or PSD-3 units, will come online in the coming weeks to tackle amorphous active pharmaceutical ingredients (APIs) and amorphous solid dispersions, according to the company. With some 80% of new small molecules in development insoluble in water, Hovione’s particle engineering and amorphous solid dispersion platform helps medicine developers improve the solubility, bioavailability, and, in some cases, the stability of their drug candidates, Basile said.  The company boasts spray dryers from the lab scale to PSD3 at its original facility in East Windsor, in addition to the pair of large-scale machines about to be activated at the campus' new facility.  “We’re going for a single, unified site with capabilities across the campus to do drug substance through finished drug product under one governance and quality system,” - Basile told Fierce.   Read the full article at FiercePharma.com

Article

As expansions come online, CDMO Hovione aims to meet industry's 'dual supply and sourcing' zeal: exec

Mar 26, 2026